HDL quality or cholesterol cargo: What really matters - Spotlight on sphingosine-1-phosphate-rich HDL

Current Opinion in Lipidology

Volumn 24, Issue 4, 2013, Pages 351-356

  Egom, Emmanuel E ^a   Mamas, Mamas A ^b   Soran, Handrean ^b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atherothrombotic; Coronary artery disease; HDL; HDL functionality; Sphingosine 1 phosphate

Indexed keywords

DALCETRAPIB; FINGOLIMOD; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE;

ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; HEART PROTECTION; HUMAN; ISCHEMIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; CARDIOTONIC AGENTS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; LYSOPHOSPHOLIPIDS; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84880574175     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328361f822     Document Type: Review

References (53)

1. Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol 2012; 23:353-366.
2. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57:392-410.
3. Subach FV, Patterson GH, Manley S, et al. Photoactivatable mCherry for highresolution two-color fluorescence microscopy. Nat Methods 2009; 6:153-159.
4. Soran H, Younis NN, Charlton-Menys V, Durrington P. Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol 2009; 20:265-274.
5. Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012; 111:1079-1090.
6. Younis NN, Soran H, Charlton-Menys V, et al. High-density lipoprotein impedes glycation of low-density lipoprotein. Diab Vasc Dis Res 2013; 10:152-160.
7. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007; 48: 2325-2333.
8. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82:201-211.
9. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
10. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256:2835-2838.
11. Ali KM, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol: current therapies and future opportunities. Br J Pharmacol 2012; 167:1177-1194.
12. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
13. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30:151-155.
14. Boden WE, Probstfield JL, Anderson T, et al., AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
15. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
16. Pyne NJ, Tonelli F, Lim KG, et al. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012; 40:94-100.
17. Watson C, Long JS, Orange C, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010; 177:2205-2215.
18. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338:b92.
19. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT - a randomized controlled trial. JAMA 2001; 285:1585-1591.
20. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
21. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-2099.
22. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
23. Haase CL, Tybjaerg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010; 95:E500-E510.
24. Haase CL, Tybjaerg-Hansen A, Qayyum AA, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54 500 individuals. J Clin Endocrinol Metab 2012; 97:E248-E256.
25. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. The Lancet 2012; 380:572-580.
26. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54:788-800.
27. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751-2756.
28. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010; 105:821-832.
29. Egom EE, Mamas MA, Clark AL. The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure. Expert Opin Ther Targets 2012; 16:791-800.
30. Egom EE, Ke Y, Solaro RJ, Lei M. Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling. Prog Biophys Mol Biol 2010; 103:142-147.
31. Carr JM, Mahalingam S, Bonder CS, Pitson SM. Sphingosine kinase 1 in viral infections. Rev Med Virol 2013; 23:73-84.
32. Machesky NJ, Zhang G, Raghavan B, et al. Human cytomegalovirus regulates bioactive sphingolipids. J Biol Chem 2008; 283:26148-26160.
33. Kobayashi N, Nishi T, Hirata T, et al. Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J Lipid Res 2006; 47:614-621; PubMed PMID: 16371645.
34. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptormediated actions. Biochem J 2000; 352 (Pt 3):809-815.
35. Hammad SM, Pierce JS, Soodavar F, et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010; 51:3074-3087.
36. Hammad SM, Al Gadban MM, Semler AJ, Klein RL. Sphingosine 1-phosphate distribution in human plasma: associations with lipid profiles. J Lipids 2012; 2012:180705.
37. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905-1919.
38. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115:501-508.
39. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113:569-581.
40. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114:1403-1409.
41. Kontush A, Therond P, Zerrad A, et al. Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007; 27:1843-1849.
42. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98:1352-1364.
43. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007; 9:493-498.
44. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8:222-232.
45. Liu D, Ji L, Wang Y, Zheng L. Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein. Cardiovasc Hematol Disord Drug Targets 2012; 12:98-105.
46. Tamama K, Tomura H, Sato K, et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 2005; 178:19-23.
47. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276:31780-31785.
48. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23:1283-1288.
49. Deutschman DH, Carstens JS, Klepper RL, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003; 146:62-68.
50. Argraves KM, Sethi AA, Gazzolo PJ, et al. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011; 10:70.
51. Tong X, Peng H, Liu D, et al. High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDLassociated sphingosine-1-phosphate. Cardiovasc Diabetol 2013; 12: 27.
52. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9:139-150.
53. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptormediated actions. Biochem J 2000; 352:809-815.